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Abstract: In controlling Rift Valley fever, public health sector optimises health benefits by considering cost-
effective control options.Wemodelled cost-effectiveness of livestockRVF control fromapublic health perspective
in Kenya. Analysis was limited to pastoral and agro-pastoral system high-risk areas, for a 10-year period incor-
porating two epidemics: 2006/2007 and a hypothetical one in 2014/2015. Four integrated strategies (baseline and
alternatives), combined from three vaccination and two surveillance options, were compared. Baseline strategy
included annual vaccination of 1.2–11% animals plus passive surveillance and monitoring of nine sentinel herds.
Compared to the baseline, two alternatives assumed improved vaccination coverage. A herd dynamic RVF animal
simulation model produced number of animals infected under each strategy. A second mathematical model
implemented in R estimated number people who would be infected by the infected animals. The 2006/2007 RVF
epidemic resulted in 3974 undiscounted, unweighted disability adjusted life years (DALYs). Improving vacci-
nation coverage to 41–51% (2012) and 27–33% (2014) 3 years before the hypothetical 2014/2015 outbreak can
avert close to 1200 DALYs. Improved vaccinations showed cost-effectiveness (CE) values of US$ 43–53 per DALY
averted. The baseline practice is not cost-effective to the public health sector.
Keywords: public health, benefits, Rift Valley fever, livestock
INTRODUCTION
Rift Valley fever (RVF) is an arthropod-borne viral zoonosis
that primarily affects domestic ruminants, humans and some
wild animals (OIE 2002, 2007). The RVF virus (RVFV) be-
longs to the Phlebovirus genus under the Bunyaviridae
family. Major RVF epizootics (in livestock) and epidemics
(in humans) have occurred in several countries in bothAfrica
and Middle East (Bird et al. 2007). In this paper, the word
outbreak is used interchangeably with epidemics or epi-
zootics and it means that reported number of RVF cases in
people and livestock is higher than normal. The last two
outbreaks in eastern Africa occurred in 1997/1998 and 2006/
2007 (Woods et al. 2002; Nguku et al. 2010; Anyangu et al.
2010). The long inter-epidemic/epizootic period (IEP) is
attributed to association between the outbreaks and occur-
rence of El Nin˜o rains. The latter are associated with
anomalous warming of sea surface temperatures in the
eastern equatorial Pacific and the western equatorial Indian
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Ocean. The above normal rains that follow the ElNino events
cause flooding especially in low-lying areas, favouring the
hatching of Aedes mosquitoes that transmit RVFV (Linthi-
cum et al. 1991; Diallo et al. 2005).
In livestock, Rift Valley fever outbreaks occur after bites
from infected mosquitoes (Linthicum et al. 1985; Davies and
Highton 1980). A majority of human infections result from
contact with blood or organs of infected animals (WHO2010;
LaBeaud et al. 2008; Sang et al. 2010; Nicholas et al. 2014),
while few result from bites by infected mosquitoes. Peaks in
human RVF incidences coincide with outbreaks (epizootics)
in livestock (Woods et al. 2002; Archer et al. 2013). Impacts of
RVF outbreaks go beyond livestock producers to affect public
health, other livestock value chain actors and connected sec-
tors of the economy (Swanepoel and Coetzer 2004; ILRI 2008;
ROK 2009; Pe´pin et al. 2010; Rich and Wanyoike 2010).
Inmanaging human RVF, governments seek to optimise
health gains by reducing number of human cases, severity or
duration of disability and deaths. In the process, budgetary
constraints introduce difficult decisions on how to allocate
limited resources. Health economists support the decisions
by providing data on disease burdens (monetary and non-
monetary) as well as cost-effectiveness of control options.
Monetary costs include control costs and opportunity costs.
Disability adjusted live years (DALYs), a non-monetary
measure recommended by World Health Organisation
(WHO), reflects premature death and reduced quality of
human life (disability) in non-fatal Cases (Murray 1994).
One DALY is equal to one lost year of ‘‘healthy life’’.
Cost-effectiveness analysis helps to prioritise public
health sector’s investments allowing decision makers to
compare financial costs and gainsmade or likely to arise from
different interventions. Expressed as cost of intervention per
DALY averted, WHO sets thresholds based on per capita
national incomes (World Health Organisation 2014). An
intervention that costs less than three times the national
annual per capita GDP is considered cost-effective, whereas
one that costs less than once the national annual per capita
GDP is considered highly cost-effective. For zoonotic prob-
lems such as RVF, gains in human health arise from both
animal and public health interventions. Therefore, examin-
ing costs and benefits at both levels and in particular benefits
to public health sectors arising from animal interventions
becomes important. Mostly, zoonotic transmission is animal
to human and not the reverse making effective interventions
to lie outside public health sector. Assessing costs and ben-
efits of control from a multisectoral perspective facilitates
identification of strategies that yield the highest benefits to
both sectors. Further, knowledge of distribution of benefits
would inform animal control cost sharing between animal
and public health sectors.
This cost-effectiveness analysis (CEA) examines im-
pacts of four livestock sector level RVF intervention
strategies on public health and identifies those that offer
highest benefits to the public health sector.
METHODOLOGY
The analysis was limited to RVF high-risk areas in pastoral
and agro-pastoral (PAP) livestock systems in Kenya, and for a
10-year period covering two epidemics—the 2006/2007 and a
hypothetical one assumed to occur in 2014/2015. Figure 1
plate A shows RVF risk zones in Kenya. The hypothetical
Plate A      Plate B 
RVF Confirmed in Livestock only 
RVF confirmed in livestock and humans 
Figure 1. Map of Kenya showing RVF risk status (plate A, source: CDC, Kenya, courtesy of Peninah Munyua) and the 2006/2007 outbreak
areas (plate B).
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2014/2015 outbreak was assumed to occur in the high-risk
areas only. High-risk zones in pastoral and agro-pastoral areas
are circled out. Figure 1 plate B shows locations where the
2006/2007 outbreak occurred. The 2006/2007 outbreak rep-
resented an actual scenario of without preventive measures: it
occurred after a 10-year period during which no measures
were applied. The 2014/2015 represented a hypothetical out-
break with control measures. It was assumed to occur after a
long inter-epidemic period during which baseline preventive
measures were actually applied. The impacts of the baseline
measures on the outbreaks were compared to those of alter-
native measures on the hypothetical 2014/2015 outbreak. In
modelling costs and benefits of animal RVF control to public
health sector, and for the case of the hypothetical 2014/2015
epidemic, the CEA took a public health partial societal per-
spective. All significant costs and benefits were considered
irrespective of who pays or benefits. The costs of control
constituted the numerator in the cost-effectiveness analysis,
while outcomes or effectiveness measure was the denominator
as cited in Gold et al. (1996).
Analytical Approach
Seven steps of CEA described in Martins and Rushton
(2014) were applied. They are summarised below—though
several stages are described together.
The Problem, Conceptual Model and Analytical Perspective
As most human RVF cases are transmitted from animals
(WHO 2010; LaBeaud et al. 2008; Sang et al. 2010; Nicholas
et al. 2014), we assumed that animal RVF control strategies
would reduce human epidemics by lowering the number of
infected animals and virus amplification cycle in these
hosts. Therefore, from a public health perspective, the need
for CEA-based prioritisation of animal control measures
was considered compelling. Information obtained from the
literature and key informants was discussed in two stake-
holder workshops. Stakeholders defined four (base strategy
and three alternates, Table 1) animal RVF interventions to
be subjected to the CEA.
The interventions were assumed to be implemented for
the period 2007–2014. Both national RVF contingency plan
(ROK 2010) and RVF Decision Support (ILRI and FAO
2009) recommend implementation of animal vaccinations
and surveillance during the inter-epidemic period in order
to minimise impacts of next outbreaks. The rationale lies in
the fact that prediction of the 2006/2007 RVF epidemic by
NASA was only three months before confirmation of dis-
ease in people (Anyamba et al. 2009). A 3-month period is
assumed to be insufficient to mount a comprehensive
preventive vaccination programme to protect animals.
Also, in Kenya, RVF outbreaks occur irregularly: the inter-
Table 1. Description of Four Animal RVF Control Strategies Assessed for Impacts.
Strategy Inter-epidemic vaccination Number (millions) of animals that would be
2012–2014 vaccinated
Surveillance option
Cattle Sheep and goats Camels
Baseline 0a 0 2.2 0 0d
Alternate 1 1b 1.2 4.5 0.6 1e
Alternate 2 2c 1.7 6.2 0.8 0
Alternate 3 0 0 2.2 0 1
aBaseline vaccination of 11% cattle, 1.2% camels and 4.8% sheep and 5.9% goats in 2007; 4.4–8.3% sheep and 6.3–8.3% goats (0% cattle and 0% camels) during
the period 2008–2014. The range reflects different proportions in different years, though generated by the model, the rates were informed by the primary data
obtained from Ministry in charge of livestock.
bVaccination option 1 comprises baseline vaccination for the period 2007–2011 followed by a shift to annual mass vaccination of 35–43% of all species and ages)
in year 2012 and 8–11% of young animals only, in all species in years 2013–2014 The range reflects different proportions in different species and years and were
generated by the model.
cVaccination option 2 comprises baseline vaccination for the period 2007–2011 followed by a shift to two annual mass vaccinations of 41–51% and 27–33% (all
species, all ages) in years 2012 and 2013, respectively. The range reflects different proportions in different species.
dBaseline surveillance option comprises a weak passive surveillance system and 9 sentinel herds monitored three times a year
eEnhanced surveillance option, defined as a combination of routine passive enhanced through implementation of a community-based RVF surveillance system
and inclusion of vector surveillance activities alongside four times a year wet season sentinel monitoring and epidemiological surveys. Community-based system
included (i) a disease community-based control committee with a focal person linked to District Veterinary Office and existing health facility’s public health
committees and (ii) a feedback mechanism between field officers and livestock keepers as a key incentive to increase community participation.
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epidemic period has been 3.6–10 years (Murithi et al.
2011), which complicates timing of measures. The base
strategy represented the actual prevailing practice imple-
mented during the period 2007–2011, and was assumed to
continue to 2014. Alternates 1 and 2 compared two en-
hanced vaccination strategies. In Alternate 1, animal vac-
cination coverage was increased by 460% (four and half
times), 67 and 78% in years 2012, 2013 and 2014, respec-
tively, over the base practice (2007–2011). In Alternate 2, it
was increased by 512% (five times) and 368% in 2012 and
2013, respectively, over the base strategy. Alternate 3 ex-
plored the impacts of enhanced surveillance, assumed to
improve early warning and reaction reducing delays in
implementing of sanitary bans by 50% (from 4 weeks with
baseline surveillance) to 2 weeks. The sanitary bans include
bans on movement and marketing of live cattle, sheep,
goats and camels and their products. A vaccinated animal
was assumed to be protected for life from the disease,
reducing the chances of infection and consequent ability to
transmit to human being.
Modelling
Models First, an individual-based dynamic C++ language
with Borland C++ builder 6 model described in detail by
Fuhrimann (2011) and highlighted in Zinsstag et al. (2015)
was constructed to support simulation of animal outbreaks.
The model quantified animal RVF transmission to generate
(i) number of cattle, camels, sheep and goats infected
during the 2006/2007 and a next hypothetical epidemic in
2014/2015 and (ii) number of animals that died, aborted or
well infected and sold or slaughtered. The model represents
in a simplified way, livestock dynamics (inflows and out-
flows disaggregated by species, age and sex categories)
during normal and drought periods. The simulation
tracked an individual animal over days and years. To ob-
serve what happened to the dynamics over the RVF out-
break periods, animals were stratified into susceptible,
exposed, infectious and recovered. The impacts of the base
and alternate strategies were modelled for the 2014/2015
epidemic period only. To model the impacts of the control
strategies on the herd dynamics, assumptions of the bio-
logical impacts of the measures on an outbreak were
incorporated. For example, vaccinated animals were re-
moved from susceptible populations. The outputs for the
hypothetical 2014/2015 outbreak reflected the extent to
which the four animal RVF control strategies reduced
number of animals infected.
Secondly, a simple compartmental model was devel-
oped to simulate human RVFV exposure from infected
animals based on the data and parameters outlined in
Tables 2 and 3. The model assumed that the human pop-
Table 2. Secondary Data on RVFV Infection Levels in Livestock and People, Obtained from Various Publications Documenting RVF
Epidemics in Various Countries in Africa.
Variables Documented RVF epidemic by country and year
Kenya 2006/07 Tanzania 2007 Egypt Mauritania 2003 Mauritania 2010
Total number of livestock in the outbreak sites areasa 11,221,797a 15,550,052 123,946 7,150,000 775,000
Seroprevalence of RVFV from all the livestock





















Number of livestock infectedc 1,575,472 1,159.440 8755.604 1,027,180 152,830
Human population in RVF infected areas (number)d 1,280,769 10,007,160 655,052 221,301 82,297
Seroprevalence of RVFV in humans (%) 0.13 0.029 0.077 0.03615 0.00039
Infected human populatione 166,500 291,889 50,439 8000 26,000
aIn Kenya, the data were derived from the 2009 census, while for the other countries, these data were obtained from FAO (FAOSTAT, 2008).
bReferences used include Nguku et al. (2010), Jost et al. (2010), Munyua et al. (2010) (Kenya), Chengula et al. (2013), Sindato et al. (2011, 2014) (Tanzania),
Heinrich et al. (2012), Sumaye et al. (2013), Kamal (2011) (Egypt), Ousmane et al. (2007, 2010) (Mauritania 2003 and 2010 outbreaks) and El Mamy et al.
(2011) (Mauritania 2010 outbreak).
cThese are estimates calculated based on seroprevalence data, except in Kenya, where they were derived from herd dynamics model.
dIn Kenya, these estimates are based on the 2009 census, while in the other countries, they are derived from United Nations (2015).
eThe infected human population is derived using the seroprevalence data and human population.
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ulation could be structured into four compartments: Sus-
ceptible (S), Exposed (E), Infectious (I) and Recovered/
Immune (R).
The total human population (N) was represented as
follows:
N ¼ Sþ E þ I þ R
The model was run for a total of 180 days, a duration
over which a typical epidemic would take to burn out, with
an internal time component of a day. These analyses were
carried out using R (version 3.1.1, Dunn 2007) and a sys-
tem of difference equations used was




Eiþ1 ¼ Ei þ Si  b ILi
TLi
 




Iiþ1 ¼ Ii þ Ei  1
IP
 
 Ii  1
RP
 
 Ii mrð Þ ð3Þ




where b represents the daily transmission rate from live-
stock to humans, IL represents the infected livestock pop-
ulation (cattle, sheep, goats and camels), TL represents the
total livestock population (cattle, sheep, goats and camels),
IP represents the latent period of RVFV, RP repre-
sents Infectious period of RVFV and mr represents case
fatality rate of the disease.
We assumed that all human cases originated from
infectious animals during the epidemic and that all animal
species were considered to have similar transmission
potential of human RVF. The authors appreciated that (i)
sheep were infected and had a higher probability of
infecting humans and (ii) some infections in humans may
result from mosquito bites. However, lack of sufficient data
to attribute transmission rates to the different livestock
species and mosquitoes leads to a situation where these
components of RVFV transmission were ignored. Based on
Anyangu et al. (2010), mosquitoes were not significant
factors in severe cases of human RVF which carry higher
disability weight.
The analyses commenced with the estimation of b for
each epidemic presented in Table 2 based on the numbers of
human and animal infections, assuming that all the infec-
tions in the human populations were acquired from the
livestock population over a period of 90 days. This period
was fixed based on observations made by Jost et al. (2010).
The difference in the cumulative number of infections gen-
erated by the model and those observed in the various epi-
demics (Table 2) was minimised so as to generate epidemic-
specific b estimate. This analysis assumed that human
exposure occurred when the prevalence of the virus in live-
stock had achieved an equilibrium level. To simulate a
hypothetical RVFV exposure in humans (in 2014), a point b
estimate was generated from a uniform distribution, with the
outbreak-specific b estimates being used to set the minimum
and maximum values of the distribution.
Identification and Estimation of Costs
Total monetary public health costs considered included the
following:
(i) Ten-year recurrent and fixed expenditures on animal
RVF control by public veterinary services and livestock
keepers. Since human health benefits from the animal
interventions would be produced without separable
control costs, we adapted basic elements of joint cost
allocation; the ‘‘separable cost-remaining benefits’’
method in multipurpose projects (Gittinger 1982) to
allocate the expenditures to both sectors in propor-
tional to benefits gained.
(ii) Household out-of-pocket costs to cater for human
cases.
Table 3. Description, Values and Sources of the Parameters Used in the Human RVFV Transmission Model.
Symbol Description Value Source
IP Latent period of RVFV 6 Ikegami and Makino (2011)
RP Duration of RVF infection 28 Nguku et al. (2010)
mr Case fatality rate of RVF 0.05 Kahlon et al. (2010) and WHO (2010)
Duration of the outbreak 90 Jost et al. (2010)
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(iii) Direct expenditures by government on diagnosis,
treatment and hospitalisation for human inpatients
and outpatients.
Costs ii and iii were estimated as a product of number
of human cases assumed to be treated and respective unit
costs obtained from Schelling and Kimani (2008) and Or-
inde (2014).
Non-direct recurrent public health sector expenditures
and fixed costs for government (salaries, surveillance,
deprecation of equipments and transport) could not be
estimated due to data and time constraints. The monetary
costs and benefits were discounted at 20%.
Identification and Determination of Benefit of Control
(Outcomes)
Effectiveness of animal interventions from a public health
perspective would be measured by the extent to which they
reduced both human cases (and therefore DALYs) and case
management costs. The DALYs lost during the two human
RVF epidemics periods—the 2006/2007 and the hypothetical
2014/2015 (with four strategies)—was estimated. The peri-
ods covered November 2006 to June 2007 and November
2014 to June 2015. Animal RVF modelling assumed that
there were no animal inter-epidemic transmissions. Hence,
inter-epidemic cases were not included. This was informed
by lack of sufficient data. Based on Murray (1994), Murray
and Lopez (1996) and Narrod et al. (2012), we estimated
DALYs as sum of (i) years of healthy life lost (YLL) due to
premature death from a standard expected years of life lost
(SEYLL) and (ii) for non-lethal cases, years of productive life
lived with disease specific disability (YLD). Similar to La-
Beaud et al. (2011a), we estimated DALYs for both acute and
chronic cases using disability weights of 0.22 and 0.62 and for
duration of 0.1 years, respectively, as follows:
DALYs ¼ YLLþ YLDacuteþð YLDchronicÞ
YLL ¼ Incdeathð Þ
 standard expected years of life lost
at median age of death

YLDacute ¼ Incacute  Dwacute  Durationacute
YLDchronic ¼ Incchronic  Dwchronic  Durationchronic;
where Inc is the Incidence and DW is the disability weight
To estimate DALYs lost during the 2006/2007 epi-
demic, the 13% IgM seroprevalence derived 185,000 hu-
man cases reported in Nguku et al. (2010) were assumed to
represent all RVF infections in the pastoral and agro-pas-
toral high-risk areas plus Kilifi district located in mixed
farming systems. The latter were excluded from this anal-
ysis. Based on the published proportions of underreported,
acute, severe and asymptomatic, the cases were disaggre-
gated as shown in Fig. 2. The disaggregation was consid-
ered realistic as the 90 deaths documented represent 1% of
1% of acute
Total RVF cases in 4 districts 185,000 
Acute -9,250 Asymptomatic -175,750 
cases
Self limiting (8244 
cases)
Severe, chronic (hemorrhagic, 
meningoencephalities, ocularities ((1006 cases)   
Survived - 916 cases Death- 90 cases 
10% of acute
95%  5%  
89%  10.9% 
Figure 2. Disaggregated incidence of the RVF cases in RVF hot spots. Total and chronic cases (survived and deaths) were sourced from Nguku
et al. (2010); proportions acute, asymptomatic and chronic were informed by Schelling and Kimani (2008), Ikegami and Makino (2011), Nguku
et al. (2010), WHO (2010) and Kahlon et al. (2010).
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the estimated acute cases. The range reported in the liter-
ature is 0.5–2.0% (LaBeaud et al. 2011a).
Asymptomatic cases were excluded from DALY analysis:
they were assumed to result in negligible disability. Demo-
graphics’ distribution (nine age categories and sex) of con-
firmed and probable cases reported inNguku et al. (2010) was
extrapolated to all acute and chronic non-fatal cases. Illness
during duration of 0.1 years (Orinde 2014) was adopted.
Years 2000 (representing 2006) and 2012 (representing 2014)
global level highest life expectancy of birth values of 78 years
and 82 for men, and 85 and 87 years for women, respectively,
were obtained fromWHOmodel life table (WHO2013). Riou
et al. (1989) and LaBeaud et al. (2008) report an upper limit of
4–10% of survivors who develop prolonged ocular and neu-
rological complications of ophthalmitis and meningoen-
cephalitis. Based on this, we assumed the chronic case rate of
10.9% from our data is close to these range.
Similar approach was used to estimate the DALYs asso-
ciated with the next assumed 2014/2015 RVF outbreak, based
on simulated total number of human cases for each control
strategy. While discounting of DALYs and age weighting are
recommended, this study estimated undiscounted and un-
weighted values. This is due to the fact that analysis was at a
sub-national population, and mainly to rank control strate-
gies. Also, there is increasing critique to discounting and age
weighting because the approach values life years lived by
people of different ages and generations differently (Anand
and Hanason 1997). The benefits were estimated as saved
monetary case management costs and DALYs averted.
Cost-Effectiveness Analysis and Sensitivity Analysis
Cost-effectiveness of the four animal control strategies was
expressed as net present value of public health allocated
costs of each control option per DALY averted. Also a
benefit cost ratio is computed to compare public health
monetary costs and allocated control costs. A discount rate
of 20% is used, assuming the base year for evaluating
control strategies was 2007. The discount rate was manually
varied by 10% for sensitivity analysis.
RESULTS
Quantity of Animal Risk Factors for Human RVF
Infection During the Two Epidemics
In PAP, animal-related risk factors include drinking raw
milk, sheltering livestock, milking animals, disposal of
aborted foetuses, assisting animal births, killing or skinning
animals, cooking meat and slaughtering animals (Woods
et al. 2002; Anyangu et al. 2010; LaBeaud et al. 2008,
2011b); the relative importance of each risk factor beha-
viour differs. Among the species, sero-positivity association
was the greatest with sheep-related activities, followed by
goats, cattle and lastly camels. Handling aborted foetuses
increased the chance of getting RVF by nearly three times.
The individual livestock dynamic model that derived
animal (all species combined) risk load for human trans-
mission is summarised in Table 4. While the numbers of
abortions are lower compared to mortality and lactating
animals, during the 2006/2007 RVF epidemic, the model
estimates close to 1.6 million animals were infected in PAP
high-risk areas, while about one thousand (1000) infected
animals were sold and slaughtered in slaughter houses lo-
cated within clean and infected areas and in the process
posing a risk to human health. More than 200 infected
animals were slaughtered at home.
For the hypothetical 2014/2015 epidemic, the two
alternate strategies with both enhanced vaccination and
surveillance (Alternates 1 and 2) reduced the number of in-
fected animals by 23–26% compared to the baseline. Alter-
nate 3 with enhanced surveillance and baseline vaccination
reduced the number of infected by less than 1%. Alternates 1
and 2 reduced number of infected animals sold and slaugh-
tered by about a half (46–54%) compared to by less than a
quarter (17–24%) in Alternate 3. Overall, Alternates 1 and 2
reduced total risk load by between 27 and 28%, while
Alternate 3 reduced total risk load by less than 1%.
Human Cases During the Hypothetical 2014/2015
RVF epidemic
The daily animal to human transmission coefficients for the
different outbreaks was estimated at 0.016% (Mauritania
2003 outbreak), 0.024% (Tanzania), 0.057% (Kenya),
0.068% (Egypt) and 0.1% (Mauritania 2010 outbreak). A
random value of 0.069% was obtained by applying a uni-
form distribution to these values. Estimated human cases
transmitted from the infected animals disaggregated by
strategy during the hypothetical 2014/2015 epidemic are
summarised in Table 5. The base animal control practice
resulted in about 158,525 human cases and 78 deaths which
are close to total incidence of 2006/2007 in the same area.
Alternates 1 and 2 decreased human cases by about a
quarter (23% and 25%) compared to baseline.
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DALYs Associated with the RVF Epidemics
Table 6 summarises the undiscounted, unweighted DALY
estimates for 2006/2007 RVF epidemic disaggregated by sex
and age categories. The total DALY burden for 2006/2007
in PAP high-risk areas was estimated at 3974.05 or 1.50
DALYs per 1000 populations of which mortality con-
tributed to 94.6%. During the hypothetical 2014/2015
epidemic, the baseline animal RVF practice resulted in 4548
DALYs (3.13 per 1000 people) which is 14% higher than
DALY burden associated with the 2006/2007. Alternate
strategies 1 and 2 showed benefits of averting 1058 and
1187 DALYs, respectively, compared to alternate that
averted only 3 DALYs.
Public Health Monetary Costs and Benefits Associ-
ated with Alternate Animal RVF Control Measures
Household Out-of-Pocket and Public Sector Expenditures on
Case Management
During the 2006/2007 RVF outbreak, household out-of
pocket expenditures on sick in and out patients ranged
from US$ 109.6–122.4 (Schelling and Kimani 2008; Orinde
2014), while public hospitals incurred an extra US$ 70.8
per patient on diagnosis, drugs and protective clothing
(Schelling and Kimani 2008). We assumed that only severe
acute (that progress to chronic) cases (associated with each
control strategy) would seek in patient medical treatment.
During the hypothetical 2014/2015 epidemic, the number
of hospitalised cases would be the highest (864) with base
strategy resulting in household out pocket and government
direct case management discounted costs of US$ 163,611.6.
Households out pocket costs would account for 63.4%.
Compared to the baseline, Alternate strategies 1 and 2
reduced the cost by 30–33%, while Alternate 3 reduced it by
9%. Direct recurrent costs not captured included recruit-
ment of additional staff and staff salary time spent on case
management and surveillance. However, during the 2006/
2007 epidemic, data obtained from Ministry of Health
showed that about US$ 1.3 million from government and
unconfirmed amount from Non-Governmental Organisa-
tions (NGOs) funded activities. The activities included case
management, community education, preventive measures
(e.g. vector control and mosquito nets), sampling and
transportation of samples, laboratory diagnosis, surveil-
lance and referrals of suspect cases.
Animal RVF Control Costs Allocated to Public Health
Table 7 column 2 presents the net present value of 8-year
(2008–2015) control costs associated with of the four ani-
mal RVF control strategies. The costs were considered as
joint costs and allocated to livestock and public heath
proportionally to benefit (saved costs). The benefits con-
sidered were those related to livestock sector (saved pro-
duction losses and households (from reduced out-of pocket
expense and avoidance of hospitalisation and drugs) and
government public heath (saved costs of treatment of sick
and hospitalised cases).
Saved public monetary costs (benefits) accounted for
0.5–0.6% (for strategies with improved vaccination, Alter-
nates 1 and 2) and 4.9% (for Alternate 3) of the total public









Total number of RVF infected animals that or are






2006/2007 Base 1,575,472 157,866 902,324 1171 231 538,442
Hypothetical
2014/2015
Base 1,744,601 162,302 931,777 8532 1345 814,208
Alternate 1 1348,598 (23)a 129,377 (20) 726,375 (22) 4642 (46) 726 (46) 594,117 (27)
Alternate 2 1,302,900 (25) 98,579 (40) 698,203 (25) 3893 (54) 678 (50) 586,594 (28)
Alternate 3 1,743,345 (0) 162,302 (0) 930,535 (0.1) 6509 (24) 1119 (17) 813,273 (0.1)
Source: Computed from the animal RVF transmission model. Livestock start population in 2006/2007 was 11.2 million (combined cattle, sheep, goats, and
camels). Start population 2014/2014, was 13.7 million.
aNumbers in brackets represent the percentage by which alternate strategies reduce risk load compared to baseline.
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and livestock sectors monetary benefit. Animal health dis-
counted costs allocated to public health were about US$
50,000–51,000 (Table 7 column 7).
Alternates 2 and 1 returned a control cost per
DALY averted of US$62 and US$ 77 and US$43 and
US$ 47, respectively, with 10 and 20% discount rate. In
2007 ( assumed decision making year), the per capital
GNI was US$ 720 (World Bank 2015). At 20%, the
benefit cost ratio (BCR), computed as saved or avoided
household out-of-pocket and public sector expenditures
on case management, divided by the allocated control
costs was about one for both strategies, showing that
saved monetary costs are equal to control costs allo-
cated.
Table 5. Number of Disaggregated Human RVF Cases and Mortality During the Hypothetical 2014/2015 Epidemic Derived from the
0.069% Daily Transmission Rate, Presented by Prevention and Control Options.
Control strategy Human cases
Total Asymptomatic (95%) Acute (5%) Self limiting acute Chronic Mortality
Baseline 158,525 150,598 7926 7062 864 78
Alternate 1 122,608 116,478 6130 5462 668 60
Alternate 2 118,461 112,538 5923 5277 646 58
Alternate 3 158,411 150,490 7921 7057 863 78
Table 6. Total DALYs for the 2006/2007 RVF High-risk Areas in PAP.
Sex Population DALY per 1000
Sex/age category Population DALYs
Males
Less than 10 years 542302 3.43 0.01
11–20 years 438,252 579.33 1.32
21–30 164,607 1743.89 10.59
31–40 109,567 325.08 2.97
41–50 80,689 51.98 0.64
51–60 48,455 38.17 0.79
61–70 24,353 79.29 3.26
71–80 8040 7.21 0.90
Over 80 9242 0.86 0.09
Total 1,425,507 2829.25 1.98
Females
Less than 10 years 485,061 3.43 0.01
11–20 years 320,577 171.01 0.53
21–30 175,934 452.11 2.57
31–40 128,036 401.61 3.14
41–50 64,008 104.65 1.63
51–60 28,028 5.14 0.18
61–70 14,823 4.29 0.29
71–80 6208 0.86 0.14
Over 80 8955 1.71 0.19
Total 1,231,630 1144.80 0.93
Grand total 2,657,137 3974.05 1.50
Source: study computation.
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DISCUSSIONS AND RECOMMENDATIONS
This study sought to demonstrate public health sector
benefits gained from controlling RVF at animal level. Due
to unavailability of animal–human RVF transmission
model at the time, we applied two separate models linked
through data. The results showed significant public health
sector monetary and non-monetary burden (DALYs)
associated with the 2006/2007 RVF epidemic in high-risk
areas in PAP systems. Considering that the systems carry
53, 66, 73 and 99.7% of the cattle, sheep, goat and camels
found in high-risk areas, and that human transmission is
mostly through animal contact, the DALYs estimated could
constitute a large proportion of the national burden.
For the same epidemic, our estimates of 3974.05 DA-
LYs are lower than higher estimates of 4035.6 reported in
Orinde (2014). The difference lies in the data used. Orinde
used a disability weight of 0.652 for all cases, and only
considered line listed cases and human population in only
three Counties. Nguku et al. (2010) report that not all line
listed cases were due to RVF. Our study considered human
population in all RVF high-risk areas in PAP system, and
used prevalence-derived incidence to accommodate for
under reporting. Both studies imply that the national
burden of RVF associated with 2006/2007 RVF outbreak
might be higher than the estimates. The animal–human
RVF transmission modelling showed that under the animal
control base strategy, the magnitude of a next hypothetical
epidemic would be nearly similar.
Total DALYs associated with the 2006/2007 and the
hypothetical 2014/2015 (under base strategy) translate to
852 annual unweighted, undiscounted DALYs, that repre-
sent 7% of the upper limit and more than twice the lower
limit of the global RVF burden reported in LaBeaud et al.
(2011a). Inherent in DALY estimation process, it is the YLL
from RVF mortality that accounts for the largest propor-
tion of DALYs estimated.
Based onWHO thresholds for cost-effectiveness (WHO
2013) and compared to baseline improved vaccination cov-
erage in camels and cattle from 0% to between 7 and 51%
(depending on species, age targeted and strategy), and sheep
and goats (1–2 fold) 2 years before an RVF epidemic can be
considered to be highly cost-effective from a public health
perspective: in terms of reduction in DALYs and direct
treatment costs for human cases. Under base practice, only
4–9% small ruminants were annually vaccinated for 7 years
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Organisation’s Choosing Interventions that are Cost-Effec-
tive (WHO-CHOICE) project indicates that an intervention
with a cost per DALY averted that is less than three times the
national annual GDP per capita is considered cost-effective,
whereas one that costs less than once the national annual
GDP per capita is considered highly cost-effective. The
strategies can significantly (23–26%) reduce DALYs. The
base practice is not cost-effective for the public health sector.
Also, the benefit cost ratio that compared allocated costs to
saved monetary costs shows that compared to baseline, the
two alternate strategieswith enhanced vaccination had aBCR
of about one, while Alternate 3 had less than 1. Higher or
equal monetary benefits over allocated costs reflect addi-
tional benefits to the DALYs averted.
Based on our models, enhancing surveillance while
keeping vaccination level at base would yield only small
benefits to the public health sector. However, effective
animal surveillance systems would allow public health
sectors to implement early public health communication to
minimise contact with infected animals. Such benefits were
not captured in our modelling. Enhanced animal surveil-
lance also supports earlier implementation of livestock
sanitary bans; and therefore, potential contacts through
slaughter and marketing activities.
However, the results must be interpreted from a per-
spective of that in modelling, animal–human transmission,
this study faced challenges as no animal–human trans-
mission model had been developed to support multisec-
toral analysis. At the same time, few datasets on joint
animal and public health outbreak investigations existed.
This study, therefore, relied on few data points from five
epidemics in four countries. Similar difficulties were re-
ported by other similar studies (LaBeaud et al. 2011a; Randi
2011), to an extent that the latter assumed that, in case of
an incursion, human RVF outbreak in Southeast Texas,
USA, would acquire spread and infection rates similar to
West Nile Virus. On the other hand, LaBeaud et al. (2011a)
presented annual global burden of RVF as a range of 353–
11,958. In addition, while animal transmission model
estimated the number of animals that would abort, be
lactating or infected and slaughtered during the outbreak in
Kenya, lack of similar data for the other four outbreaks in
other countries denied the authors an opportunity to
modifying the transmission based on relative risk. Further,
due to the same data and modelling challenges, we com-
bined all animal species data which make it hard to tease
apart the relative contribution from different risk factors
such as drinking un-boiled milk as fewer people would
drink raw milk from sheep, goats and cattle compared to
camels.
To overcome these challenges, and particularly to
strengthen One Health economic analysis of zoonotic dis-
eases, there is a need for future joint epidemiological
investigations to generate data to support animal–human
RVF epidemiological modelling. Also, there is need for
public health studies that estimate (i) the relative contri-
bution of different public health measures such as
surveillance and communication to the outcome of the
epidemic and (ii) animal–human contact rates and trans-
mission probabilities. Generating longitudinal data on
human and livestock cases during both the epidemics and
inter-epidemic and scale of measures applied would sup-
port modelling of livestock-human transmission as was the
case of brucellosis modelling in Mongolia in Roth et al.
(2003).
Further, in modelling the magnitude of the hypothet-
ical 2014/2015 RVF epidemic, we assumed that changes in
human behaviour prior to and during epidemics would not
change and therefore, the same force of infection is main-
tained. This was influenced by observations that the PAP
areas are under developed, and receive relatively lower
quantity and quality of health services including commu-
nity-based communication for behaviour change. Conse-
quently, therefore, incidences of zoonosis are higher than in
other farming systems as shown in the case of brucellosis
(Regassa et al. 2009; Racloz et al. 2013) and anthrax
(Nkedianye and Herrero 2007). Some risk factors for hu-
man brucellosis and anthrax such as living close proximity
to livestock, handling livestock and consumption of raw
products are similar to those of RVF. Owange et al. (2014)
highlight pastoralist’ perception where mosquito bites are
perceived as the key risk factors compared to contact with
infected livestock and livestock products which are contrary
to other studies (Woods et al. 2002; Anyangu et al. 2010).
Finally, we note that errors could have resulted from the
modelling process where two models are used to arrive at
this cost-effectiveness analysis. The errors could have made
the model less sensitive to changes in some of the key
processes being studied.
While the results show that increasing peace time
animal vaccination coverage reduces the magnitude of
human outbreaks, the baseline practice shows that national
governments seem to find it difficult to achieve good
coverage levels as the risk is perceived to be low. While new
vaccines are being developed including multivalent ones
that might be possible to be applied more frequently
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alongside those of other diseases, vaccination coverage for
all diseases is considered to be lower than expected. A better
strategy—e.g. routine vaccination at a given coverage and a
reactive vaccination when a risk warning is given to shore-
up the desired levels of coverage—is required. Despite that
enhanced surveillance is expected to reduce potential
number of human cases following early implementation of
sanitary bans, the modelling failed to capture this dynam-
ics. Therefore, the real value of animal surveillance in terms
of reducing human could not be explicitly explained. To
better respond to future outbreaks, contingency plans and
decision support tools are suggesting more pragmatic ef-
forts of implementing surveillance.
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